Questions arise over reference pricing system

Published: 2002-08-26 07:00:00

Updated: 2002-08-26 07:00:00

Although the government reiterated the reference pricing system (RPS) will prevent the abuse of high-priced drugs and bring about a reduction in insurance cost, the pharmaceutical firms and civil groups oppose the plan, claiming that the new system will impair the sound drug market atmosphre and ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK